Handa Pharmaceuticals, Inc.
Research Handa Pharmaceuticals, Inc. (6620.TWO) on Bullrun: market cap TWD 22.19B, P/E 44.6, dividend yield 1.5%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6620.TWO
- ExchangeTWO
- CountryTaiwan
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyTWD
- Market capTWD 22.19B
- P/E44.6
- Dividend yield1.5%
- Financial periodQ2 2026
- RevenueTWD 211.95M
- Net incomeTWD 31.63M
- Free cash flowTWD 262.00M
- Gross margin79.9%
Valuation Snapshot
latest market cap is TWD 22.19B; P/E is 44.6; dividend yield is 1.5%.
Peer valuation comparison
Latest P/E is 44.61x versus a Healthcare sector median of 21.8x (104.7% above).
Latest dividend yield is 1.52% versus a Healthcare sector median of 2.4% (36.7% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-11 | TWD 22.19B | 44.6 | 1.7% | 2.07 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 2.07 TWD, yield 1.5%.
About Handa Pharmaceuticals, Inc.
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Phyrago, an oral kinase inhibitor used to treat chronic myeloid leukemia and acute lymphoblastic leukemia; Tascenso ODT for the treatment of multiple sclerosis;
ETFs that hold Handa Pharmaceuticals, Inc.
US-listed ETFs
Handa Pharmaceuticals, Inc. is held by 2 US-listed ETFs, going by the latest portfolios they filed with the SEC, most traded first:
| ETF | Weight | Fee |
|---|---|---|
| State Street SPDR Portfolio Emerging Markets ETF (SPEM) | <0.01% | 0.07% |
| State Street SPDR S&P Emerging Markets Small Cap ETF (EWX) | 0.02% | 0.65% |
Portfolios as filed with the SEC on Form N-PORT, dated June 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Handa Pharmaceuticals, Inc.'s market cap?
Handa Pharmaceuticals, Inc.'s market capitalization is TWD 22.19B.
What is Handa Pharmaceuticals, Inc.'s P/E ratio?
Handa Pharmaceuticals, Inc.'s price-to-earnings (P/E) ratio is 44.6.
Does Handa Pharmaceuticals, Inc. pay a dividend?
Handa Pharmaceuticals, Inc. has a dividend yield of 1.5%.
What does Handa Pharmaceuticals, Inc. do?
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Phyrago, an oral kinase inhibitor used to treat chronic myeloid leukemia and acute lymphoblastic leukemia; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases.